Bristol-Myers Squibb (BMY 0.34%) is one of the globe's top drugmakers and a staple in dividend investors' portfolios.
Big drug companies such as Bristol-Myers, Johnson & Johnson (JNJ -0.46%), and Merck (MRK 0.37%) offer investors predictable, dividend-boosting revenue regardless of the economy's whims and whispers. But investors are correct to wonder if Bristol-Myers' dividend can be sustained following the loss of patent protection on the company's top-selling drug Plavix two years ago and in light of billions more in at-risk revenue tied to future patent expirations.
In the following slideshow you'll see whether I think Bristol's dividend is safe and gain insight into how Bristol-Myers matches up with industry peers.
